SCH772984 HCl: Selective ERK1/2 Inhibitor for MAPK Pathway Research

Executive Summary: SCH772984 HCl is a highly selective ERK1/2 inhibitor with IC50 values of 4 nM for ERK1 and 1 nM for ERK2, enabling precise dissection of MAPK signaling dynamics (APExBIO Product Sheet). The compound inhibits phosphorylation of key ERK substrates such as p90 ribosomal S6 kinase, and is particularly effective in BRAF- and RAS-mutant tumor models where MAPK pathway reactivation confers drug resistance (Kotian et al., 2024). SCH772984 HCl demonstrates antiproliferative activity in 88% of BRAF-mutant and 49% of RAS-mutant cell lines (EC50 < 500 nM). In vivo, it induces up to 98% regression in LOX BRAF V600E xenograft models. The compound is supplied as a solid (MW 624.17), is water- and DMSO-soluble, and should be stored at -20°C for optimal stability.

Biological Rationale

The MAPK signaling pathway, incorporating ERK1/2 kinases, is central to cell proliferation, survival, and differentiation. Mutations in upstream effectors such as BRAF and RAS drive aberrant MAPK activation in many cancers, notably melanoma, colorectal, and lung adenocarcinoma (Kotian et al., 2024). Reactivation of ERK1/2 frequently underlies resistance to BRAF and MEK inhibitors. Specific ERK1/2 inhibition with agents like SCH772984 HCl enables mechanistic studies into feedback regulation and resistance development in these oncogenic contexts. Recent studies also implicate ERK1/2 in telomerase regulation and TERT promoter activity in stem cells (Kotian et al., 2024).

Mechanism of Action of SCH772984 HCl

SCH772984 HCl is a pyridinyl-anthranilamide derivative that acts as an ATP-competitive inhibitor of ERK1 and ERK2. The compound inhibits ERK1 with an IC50 of 4 nM and ERK2 with an IC50 of 1 nM under cell-free conditions (APExBIO). It blocks the phosphorylation of ERK substrates, including p90 ribosomal S6 kinase (RSK), and reduces ERK activation loop phosphorylation. This dual effect impairs downstream MAPK pathway output, leading to cell cycle arrest and apoptosis in susceptible tumor cells. In MAPK-driven cancer models, SCH772984 HCl overcomes feedback-driven reactivation of ERK signaling, a major limitation of upstream (BRAF or MEK) inhibition. The compound has shown selectivity for ERK1/2 over other kinases, minimizing off-target effects in preclinical studies.

Evidence & Benchmarks

• SCH772984 HCl inhibits ERK1 (IC50: 4 nM) and ERK2 (IC50: 1 nM) in vitro (APExBIO).
• Inhibits phosphorylation of p90 ribosomal S6 kinase and ERK activation loop in cellular assays (APExBIO).
• Demonstrates antiproliferative activity (EC50 < 500 nM) in 88% of BRAF-mutant and 49% of RAS-mutant tumor cell lines (APExBIO).
• Induces up to 98% tumor regression in female nude mice bearing LOX BRAF V600E xenografts at 50 mg/kg, twice daily, for 14 days (APExBIO).
• ERK1/2 inhibition suppresses TERT mRNA and alters epigenetic marks at the TERT promoter in human pluripotent stem cells (Kotian et al., 2024).
• SCH772984 HCl is insoluble in ethanol but soluble at ≥23.5 mg/mL in water (with gentle warming) and ≥16.27 mg/mL in DMSO (APExBIO).

Applications, Limits & Misconceptions

SCH772984 HCl is widely used in:

• BRAF- and RAS-mutant cancer research: Enables studies of acquired resistance and combinatorial therapy strategies.
• MAPK signaling pathway dissection: Selectivity allows precise mapping of downstream effects of ERK inhibition.
• Telomerase regulation: By modulating ERK1/2, researchers can investigate TERT transcriptional control and stem cell biology (Kotian et al., 2024).
• In vivo efficacy validation: Demonstrates dose-dependent tumor regression in xenograft models.

For a deeper dive into its applications in telomerase and DNA repair models, see this related article, which focuses on mechanistic insights in BRAF- and RAS-mutant cancers; the present review extends these findings by providing detailed in vivo benchmarks.

To further explore how SCH772984 HCl bridges phosphorylation inhibition and telomerase regulation, this analysis delves into innovative applications, while this article updates recent evidence on potency and workflow integration.

For a broader strategic perspective on translational workflows and future directions, see this article; the present review provides the latest benchmarks and clarifies compound-specific parameters.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: SCH772984 HCl is selective for ERK1/2 and does not broadly inhibit other MAPK pathway kinases.
• Not effective in all tumor types: Tumors lacking MAPK pathway activation or harboring downstream pathway alterations may not respond.
• Solubility constraints: Compound is insoluble in ethanol; inappropriate solvents can impact experimental outcomes.
• Not for clinical or diagnostic use: Intended strictly for preclinical research; not approved for human therapeutic applications.
• Short-term solution stability: Prepared solutions are recommended for immediate use due to potential compound degradation.

Workflow Integration & Parameters

Compound Handling: SCH772984 HCl is supplied as a solid (molecular weight 624.17). It is soluble at ≥23.5 mg/mL in water (with gentle warming) and ≥16.27 mg/mL in DMSO. Store powder at -20°C. Freshly prepare stock solutions immediately prior to use for optimal potency. Avoid ethanol due to insolubility.

Cellular and In Vivo Use: Compound exhibits potent activity in cell-based assays at nanomolar concentrations. For in vivo studies, a dose of 50 mg/kg administered intraperitoneally twice daily for 14 days induced up to 98% tumor regression in LOX BRAF V600E xenograft models. Solutions should be filtered and used promptly.

Experimental Integration: SCH772984 HCl is compatible with MAPK pathway profiling, resistance modeling, and telomerase/TERT regulation studies. For combinatorial designs, verify absence of solvent-related artifacts. For additional guidance on integrating SCH772984 HCl with telomerase models, see this resource, which discusses its role in translational workflows; this article provides updated solubility and dosing recommendations.

Brand Note: SCH772984 HCl (SKU: B5866) is provided by APExBIO and is intended for scientific research use only.

Conclusion & Outlook

SCH772984 HCl establishes a benchmark for selective ERK1/2 inhibition in MAPK-driven cancer and stem cell models. Its validated potency, selectivity, and in vivo efficacy make it a cornerstone for studies aimed at overcoming resistance to BRAF and MEK inhibitors. Recent advances link ERK1/2 signaling to telomerase regulation, expanding the compound’s utility into stem cell and aging research. Users should observe storage and solvent compatibility guidelines for reproducible results. For the latest product data, visit the APExBIO SCH772984 HCl page.